Journal
ADVANCED SCIENCE
Volume 6, Issue 2, Pages -Publisher
WILEY
DOI: 10.1002/advs.201801254
Keywords
circulating tumor cells; GO Chip; microfluidics; prostate cancer; RNA expression
Categories
Funding
- National Institutes of Health (NIH) Director's New Innovator Award [1DP2OD006672-01]
- Department of Defense (DoD) Office of the Congressionally Directed Medical Research Programs (CDMRP) Career Development Award
- DOD Physician Research Training Award [W81XWH-14-1-0287]
- Prostate Cancer Foundation
- A. Alfred Taubman Medical Research Institute
- National Science Foundation Graduate Research Fellowship Program [DGE 1256260]
Ask authors/readers for more resources
Rates of progression and treatment response in advanced prostate cancer are highly variable, necessitating non-invasive methods to assess the molecular characteristics of these tumors in real time. The unique potential of circulating tumor cells (CTCs) to serve as a clinically useful liquid biomarker is due to their ability to inform via both enumeration and RNA expression. A microfluidic graphene oxide-based device (GO Chip) is used to isolate CTCs and CTC clusters from the whole blood of 41 men with metastatic castration-resistant prostate cancer. Additionally, the expression of 96 genes of interest is determined by RT-qPCR. Multivariate analyses are conducted to determine the genes most closely associated with overall survival, PSA progression, and radioclinical progression. A preliminary signature, comprising high expression of stemness genes and low expression of epithelial and mesenchymal genes, potentially implicates an undifferentiated CTC phenotype as a marker of poor prognosis in this setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available